---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-005624"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:03:41.179763+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Monopar names Prof. Rodney Hicks lead investigator for MNPR-101-Zr Phase 1 trial

## Summary
- Professor Rodney Hicks to lead MNPR-101-Zr Phase 1 dosimetry trial in advanced cancer patients.
- Trial will use Siemens Biograph Vision Quadra total-body PET/CT, one of the most sensitive clinical scanners.
- MNPR-101-Zr targets cancers with high unmet need, including pancreatic and triple-negative breast cancer.
- Enrollment expected to begin shortly at Melbourne Theranostic Innovation Centre (MTIC).

## SEC filing metadata
- accession: 0001437749-24-005624
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924005624/0001437749-24-005624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924005624/mnpr20240226_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-005624
- JSON: https://secwatch.observer/filing/0001437749-24-005624.json
- Plain text: https://secwatch.observer/filing/0001437749-24-005624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.